INVA - Innoviva, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
16.44
-0.30 (-1.79%)
At close: 4:00PM EST

16.74 +0.30 (1.82%)
After hours: 5:00PM EST

Stock chart is not supported by your current browser
Previous close16.74
Open16.72
Bid13.20 x 300
Ask15.74 x 100
Day's range16.33 - 16.86
52-week range11.02 - 17.21
Volume784,992
Avg. volume998,718
Market cap1.776B
Beta2.59
PE ratio (TTM)14.05
EPS (TTM)1.17
Earnings date25 Apr 2018 - 30 Apr 2018
Forward dividend & yield0.00 (0.00%)
Ex-dividend date2015-09-08
1y target est13.25
Trade prices are not sourced from all markets
  • Business Wire7 days ago

    GSK Submits Landmark IMPACT Data to European Medicines Agency to Support Expanded Label for Trelegy Ellipta

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’) in Europe for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (for the relief of symptoms and reduction of exacerbations, see section 5.1). Approval of the submission would mean FF/UMEC/VI, the only once-daily single inhalation triple therapy for the treatment of COPD, could be used by physicians to treat a wider population of patients with the condition who are at risk of an exacerbation and require triple therapy.

  • Business Wire7 days ago

    GSK Submits Landmark IMPACT Data to European Medicines Agency to Support Expanded Label for Trelegy Ellipta

    GlaxoSmithKline plc and Innoviva, Inc. today announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy Ellipta in Europe for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease .

  • Why Innoviva Inc. Stock Jumped Tuesday
    Motley Fool7 days ago

    Why Innoviva Inc. Stock Jumped Tuesday

    An activist hedge fund is shaking things up at Innoviva.

  • Associated Press12 days ago

    Innoviva beats Street 4Q forecasts

    The Brisbane, California-based company said it had profit of 45 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...

  • Business Wire12 days ago

    Innoviva Reports Record Fourth Quarter and Full Year 2017 Financial Results

    Innoviva, Inc. today reported financial results for the fourth quarter and full year 2017. Gross royalties earned on net sales of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA® from Glaxo Group Limited during the fourth quarter of 2017 were $70.5 million, up 51% from $46.8 million in the fourth quarter of 2016.

  • Business Wire18 days ago

    Innoviva to Report Fourth Quarter Financial Results on February 8 at 5:00 p.m. EDT

    Innoviva, Inc. announced today that it will report financial results for the fourth quarter and year ended December 31, 2017 after market close on February 8, 2017. Following the earnings release, Innoviva management will host a webcast and conference call at 5:00 p.m.

  • Business Wire26 days ago

    GSK Announces CHMP Positive Opinion for Labelling Update to Relvar Ellipta in Patients with Asthma

    LONDON & BRISBANE, Calif.--(BUSINESSWIRE)-- GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products ...

  • Business Wire26 days ago

    GSK Announces CHMP Positive Opinion for Labelling Update to Relvar Ellipta in Patients with Asthma

    GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending a label update for the use of once-daily Relvar Ellipta , an inhaled corticosteroid / long-acting β2-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting ...

  • Reuters - UK Focus26 days ago

    AstraZeneca's 3-in-1 inhaler helps COPD patients in trial

    AstraZeneca (NYSE: AZN - news) said an inhaler for chronic obstructive pulmonary disease (COPD) delivered improved lung function in a late stage trial that could challenge GlaxoSmithKline (Other OTC: GLAXF - news) 's new three-in-one inhaler. The inhaler, PT010, showed "statistically significant" improvement in eight of nine main lung function goals in patients with moderate to very severe COPD, the company said on Friday.

  • Innoviva Sees RS Rating Rise To 74
    Investor's Business Daily2 months ago

    Innoviva Sees RS Rating Rise To 74

    A Relative Strength Rating upgrade for Innoviva shows improving technical performance. Will it continue?

  • Innoviva Earns Relative Strength Rating Upgrade
    Investor's Business Daily2 months ago

    Innoviva Earns Relative Strength Rating Upgrade

    Innoviva shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

  • Business Wire2 months ago

    Innoviva and Sarissa Implement Court Order

    Innoviva, Inc. today announced it implemented the Delaware Court of Chancery’s order enforcing the oral settlement agreement with Sarissa Capital Domestic Fund LP and certain of its affiliates in connection with the Company’s 2017 annual meeting of stockholders, held on April 20, 2017.

  • Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler
    Zacks3 months ago

    Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler

    Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.

  • Business Wire3 months ago

    GSK Submits Landmark IMPACT Data to US Regulatory Authority to Support Expanded Label for Trelegy Ellipta

    GlaxoSmithKline plc and Innoviva, Inc. today announced the filing of a supplemental New Drug Application with the US Food and Drug Administration for the use of Trelegy Ellipta for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease .

  • Business Wire3 months ago

    GSK Submits Landmark IMPACT Data to US Regulatory Authority to Support Expanded Label for Trelegy Ellipta

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) for the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’) for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). Approval of this sNDA means FF/UMEC/VI could be used by physicians to treat a wider population of patients with COPD who are at risk of an exacerbation and require triple therapy. It contains an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta2-adrenergic agonist, delivered once daily in GSK’s Ellipta dry powder inhaler, which is used across the entire new portfolio of inhaled COPD medicines.

  • Theravance Shares Rise on Approval of Glaxo's COPD Therapy
    Zacks3 months ago

    Theravance Shares Rise on Approval of Glaxo's COPD Therapy

    Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.

  • Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU
    Zacks3 months ago

    Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU

    Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.

  • Reuters - UK Focus3 months ago

    Europe approves GlaxoSmithKline's new triple lung drug

    Europe has approved GlaxoSmithKline's new three-in-one inhaler for chronic lung disease, which the group hopes will help it keep its lead in respiratory medicine despite falling sales of older drug Advair. ...

  • Business Wire3 months ago

    Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Gains Marketing Authorisation in Europe for the Treatment of COPD

    GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.

  • Business Wire4 months ago

    Innoviva to Participate at the Credit Suisse and Stifel Annual Healthcare Conferences in November

    Innoviva, Inc. today announced that management will present at the following healthcare-focused investment banking conferences in November 2017:

  • Business Wire4 months ago

    GSK Study Demonstrates Superiority of Anoro Ellipta to Stiolto Respimat in Improving Lung Function in Chronic Obstructive Pulmonary Disease

    LONDON--(BUSINESSWIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive data from a study comparing a once-daily long-acting muscarinic antagonist (LAMA) ...

  • Associated Press4 months ago

    Innoviva misses 3Q profit forecasts

    The Brisbane, California-based company said it had profit of 21 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • Why Did Innoviva, Inc. Stock Fall Nearly 16% Wednesday?
    Motley Fool4 months ago

    Why Did Innoviva, Inc. Stock Fall Nearly 16% Wednesday?

    Just before Innoviva released its third-quarter results on Wednesday afternoon, the stock fell sharply. What gives?

  • Business Wire4 months ago

    Innoviva Reports Third Quarter 2017 Financial Results and Provides Business Updates

    Innoviva, Inc. today reported financial results for the third quarter of 2017. Gross royalties earned on net sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® from Glaxo Group Limited during the third quarter of 2017 were $51.9 million, up 42% from $36.5 million in the third quarter of 2016.

  • Business Wire4 months ago

    Innoviva to Report Third Quarter Financial Results on October 25 at 5:00 p.m. EDT

    Innoviva, Inc. announced today that it will report financial results for the third quarter ended September 30, 2017 after market close on Wednesday, October 25, 2017.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes